1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients.
Level 5 - mechanism / opinion, no new human data
Ex vivo cellular mechanistic bench research on isolated human macrophages and in silico docking
PubMed 19433889 · doi:10.3233/JAD-2009-1080
What was done
Macrophages isolated from Alzheimer's disease (AD) patients were treated with 1alpha,25-dihydroxyvitamin D3 (1,25D3) alone and in combination with curcuminoids to evaluate amyloid-beta (Abeta) phagocytosis, clearance, and cell apoptosis. The pathway was evaluated using the 1,25D3 genomic antagonist MK and in silico docking against the vitamin D receptor.
What was found
AD patient macrophages segregated into Type I (curcuminoid-responsive for MGAT-III transcription) and Type II (non-responsive). 1,25D3 stimulated Abeta phagocytosis and clearance while protecting against apoptosis in both types. Combining synthetic curcuminoids with 1,25D3 produced additive phagocytic effects in Type I but not Type II macrophages. MK inhibited 1,25D3 effects but not curcuminoid effects. In silico, 1,25D3 bound preferentially to the genomic pocket of the vitamin D receptor, while bisdemethoxycurcumin favored the non-genomic pocket. The abstract reports no numerical values, effect sizes, or statistical significance metrics.
Why it matters
This study outlines potential cellular and receptor-level mechanisms by which vitamin D3 and curcuminoids might cooperate to stimulate innate immune clearance of Abeta in AD.
Limits
This is an ex vivo cell culture and computational study without clinical outcome testing in vivo. The abstract omits sample size (n), patient donor characteristics, and quantitative data.
Cited by
- partial Curcumin combined with vitamin D decreases amyloid plaques associated with Alzheimer's disease.